Approved, unfunded, S29 - medications in New Zealand

Approved, unfunded, S29 - medications in New Zealand

With the shortage of Estradot I’ve seen quite a few people wondering what all the different ways medication is described in New Zealand actually mean. What is an unapproved medication? What is a special authority? Hopefully I’ll answer that!

This isn’t an exhaustive list, just the ones you’re likely to see.

Funding (and Pharmac)

Lets start with the funding because it’s the easiest to understand, this comes from Pharmac - the buyer of most medication prescribed in New Zealand. There are four common funding states - unfunded, partially funded, fully funded, and special authority.

I’m only discussing the community schedule which you can handily search online - just put a medication brand or generic name in the search box to find out the funding status.

Pharmac have a set budget so fund the medications they believe will have the most impact for the amount they cost.

Unfunded

This is the easiest one - unfunded medications do not have any funding from Pharmac, you’ll pay the full market price.

Partially funded

Some less-common medications attract partial funding, for example some preparations of povidone-iodine are partially funded, so you’ll pay the market price less the Pharmac funding. For example Betadine Skin Prep attracts a $1.63 subsidy but the remainder has to be paid by the patient.

Fully funded

This is the most common state for medications prescribed in New Zealand. These are the ones that (from July 2023) are free to collect from the pharmacy as Pharmac pays the full cost of the medicine. However…

Funding restrictions

Sometimes there are funding restrictions, generally due to cost of medicine or likelihood of wastage. A great example is the Estradot oestradiol patch. These are funded for a maximum of two per week, or 8 per 28 days, so if you need 200mcg at a time you have to pick up the second pack yourself. Fortunately this is only around $18 per 8 patch box.

These restrictions are only on quantity supplied - either minimum, maximum, or only in whole packs.

For both partially and fully funded medications Pharmac will fund any use, they just pay the pharmacies. However there’s a case where they do care about the reason, so we have

Special Authority

Special Authority funding is for medications where Pharmac only fund for specific conditions or cases. These require a form to be filed with the pharmacy and Pharmac to get the subsidy - which may be full or partial - and a renewal of authority on a schedule. An example that comes to mind is the ADHD medication Concerta. Concerta is only available for patients who have some reason to not take the immediate-release versions, either addiction liability, lack of response, or an allergy to the ingredients (Ritalin IR contains wheat!).

Special Authority doesn’t prevent prescription, only Pharmac subsidy. The Utrogestan brand of micronised progesterone used to be special authority for funding (only specific cases of menopausal HRT) but could be freely prescribed, as long as patients would pay the full price (around $25 for 28 days if I recall).

So that’s funding. However funding isn’t the full picture, what about approved and unapproved? Section 29? These are nothing to do with Pharmac, so now we introduce the other half of the equation, Medsafe.

Approval (and Medsafe)

Medsafe are the regulator of medicines in New Zealand. Most medicines have MedSafe approval and approved indications, but practitioners can prescribe unapproved medicines. So lets look at these

Approved Medicines

Medsafe are an industry-funded government department, this means that if you want an approved medicine in New Zealand you have to pay the Medsafe fee. It costs between $50,000 and $110,000 to get a medication approved, plus the costs of getting the required data in to the format Medsafe need. This means that manufacturer or importer won’t apply for approval for medication unless they think they’ll be able to make their money back.

Unapproved indications

As an aside, Medsafe approval only covers conditions specified in the application for approval. However nothing stops an approved medication being prescribed for an unapproved indication - also known as “off label” - such as bupropion which is only approved as an aid to smoking cessation but is also used as an antidepressant.

Unapproved medications and Section 29 of the Medicines Act 1981

Because approval is industry-driven when they wrote the Medicines Act they realised that sometimes an unapproved medicine will be needed, for example with rare conditions or new medicines before approval is obtained. So Section 29 allows any doctor (specifically a doctor, not a nurse practitioner or pharmacist) to prescribe any unapproved medicine. However this must be reported to Medsafe by the supplier, Medsafe use this to monitor the use of unapproved medicines and direct practitioners to use approved ones where possible.

Section 29 prescriptions are for a named patient and a specific brand, so pharmacies can only supply the exact brand and quantity asked for (or an approved generic substitute, but in general that wouldn’t happen for an S29 prescription).

Additionally Section 25 allows a practitioner or pharmacist to import a medicine not otherwise available in New Zealand.

How this relates to Estradot

Estradot - and oestradiol patches in general - are in short supply worldwide. Estradot is the only patch that is approved for sale by Medsafe, and also fully funded (*with restriction to one pack per month 😞) by Pharmac.

Due to the shortage Pharmac have sourced alternate patches, Estraderm MX and Oestradiol TDP Mylan, but these are unapproved. This means there’s an odd situation where a doctor has to prescribe Estraderm MX under S29, but these are still fully funded because approval and funding aren’t linked. Pharmacies can legally substitute approved Estradot for unapproved Estraderm MX, but not the other way around.

I hope this makes things a little more clear…

An aside - controlled drugs

Completely unrelated to the above, controlled drugs are specified by the Misuse of Drugs Act 1975. There is no prohibition for prescribing controlled drugs - and in fact all classes of controlled drugs are available if hospital only use is considered. Medsafe and Pharmac do not consider the controlled status, only the medical utility. Controlled drugs can be prescribed under S29 if the prescriber can justify the use - this is how medicinal cannabis is currently managed.

Comments

Post a comment